Ask AI
ProCE Banner Activity

Early Recognition and Comprehensive Care in HS: Expert Perspectives to Your Frequently Asked Questions

Clinical Thought

Healthcare professionals managing hidradenitis suppurativa (HS) must weigh multiple moving parts at once, including disease severity; treatment stacking, dosing, and escalation; procedural needs and wound care; and patient expectations. Take home expert-informed strategies on identifying HS early via detailed physical examinations, distinguishing inadequate treatment response from persistent tunnels that call for a surgery referral, and structuring follow-up around a coordinated HS care plan that keeps pace with each patient's unique disease course.

Released: September 01, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with the HS Foundation

ProCE Banner

Supporters

Supported by educational grants from Incyte Corporation and UCB Inc.

Incyte Corporation

UCB Inc.

Partners

HS Foundation

ProCE Banner

Target Audience

This activity is intended for nurse practitioners and physician associates who care for people living with hidradenitis suppurativa.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Devise comprehensive care plans that address QoL and comorbidities for patients with HS

Financial Disclosures

Primary Author

Laura P. Bush, DMSc, PA-C, DFAAPA: consultant/advisor/speaker: Galderma, Incyte, Johnson & Johnson, Leo, Lilly, L'Oréal, Novartis, Organon, Takeda, UCB; individual publicly traded stock/stock options: Bristol Myers Squibb, Vertex.